Corvaltab - a drug with a sedative, hypnotic effect.
Release form and composition
Korvaltab is produced in the form of tablets: round with chamfers and a flat surface, white or almost white with splashes, with a specific smell (10 pieces in blisters, 2 or 10 blisters in a carton box).
The composition of 1 tablet contains the active substances:
- Ether alpha-bromizovalerianic acid - 8.2 mg;
- Phenobarbital - 7.5 mg;
- Mint oil - 0.58 mg.
Auxiliary components: beta-cyclodextrin, potato starch, lactose monohydrate, microcrystalline cellulose, magnesium stearate.
Indications for use
- Neurosis, accompanied by increased irritability;
- Hypertension and vascular dystonia (as part of complex therapy);
- Tachycardia, not pronounced spasm of the coronary vessels;
- Intestinal spasms caused by neurovegetative disorders (as a spasmolytic drug).
- Hepatic porphyria;
- Severe renal and / or liver dysfunction;
- Severe heart failure;
- Children's age (due to the lack of data on the efficacy and safety of use of the drug by this age group of patients);
- Pregnancy and lactation;
- Hypersensitivity to the drug.
Drugs containing phenobarbital are contraindicated in acute myocardial infarction, severe hypotension, depression, diabetes, myasthenia, respiratory diseases with dyspnea, drug and drug dependence, alcoholism and obstructive syndrome.
Dosing and Administration
Doses and duration of treatment are determined by the doctor individually.
Usually, adults are prescribed 1-2 tablets 2-3 times daily before meals.
For spasms of the coronary vessels and tachycardia, a single dose can be increased to 3 tablets.
As a rule, Corvaltab is well tolerated.
In some cases, the development of disorders on the part of some body systems is possible:
- Nervous system: ataxia, weakness, nystagmus, impaired motor coordination, hallucinations, decreased concentration, paradoxical arousal, fatigue, inhibition of reactions, cognitive impairment, headache, drowsiness, confusion, slight dizziness;
- The digestive system: a feeling of heaviness in the epigastric region, constipation, with prolonged use - nausea, functional disorders of the liver, vomiting;
- Cardiovascular system: arterial hypotension, bradycardia;
- Hematopoietic systems: thrombocytopenia, anemia, agranulocytosis;
- Immune system: hypersensitivity reactions, including angioedema, allergic reactions (including itching, skin rash, urticaria);
- Musculoskeletal system: with prolonged use - the risk of disruption of osteogenesis;
- Skin and mucous membranes: Stevens-Johnson syndrome, toxic epidermal necrolysis;
- Other: difficulty breathing.
Prolonged use of bromine-containing drugs can lead to bromine poisoning, which is characterized by depression of the central nervous system, depressed mood, confusion, ataxia, apathy, conjunctivitis, rhinitis, tearing, acne, or purpura.
These phenomena pass with a decrease in dose or discontinuation of Corvaltab.
Alcohol should not be taken while taking Corvaltab.
Part of the drug phenobarbital may lead to the risk of developing Stevens-Johnson syndrome and Lyell, which most likely can occur in the first weeks of treatment.
Prolonged use of Corvaltab is not recommended due to the risk of drug dependence, possible accumulation of bromine in the body and poisoning with it.
In cases where the pain in the heart does not decrease, you need to consult a doctor to rule out acute coronary syndrome.
Caution requires the use of Corvaltab for arterial hypotension, hyperthyroidism, hyperkinesis, hypofunction of the adrenal glands, acute and persistent pain, acute intoxication with drugs.
The drug contains lactose, so it is not recommended to use Corvaltab in patients with hereditary lactose intolerance-galactose.
During therapy, one should not engage in activities that require increased attention, fast motor and mental reactions, including driving.
While taking Corvaltab with other drugs that depress the central nervous system, mutual reinforcement of action is possible.
Phenobarbital induce liver enzymes, and, accordingly, may accelerate the exchange of some drugs that are metabolised by liver enzymes (including cardiac glycosides, indirect anticoagulants, antiepileptics, antimicrobial, antifungal, antiviral, anticonvulsant, psychotropic, hormonal, oral saharponizhayuschie, immunosuppressive, antiaritimicheskie, cytostatics, antihypertensives medicines).
Corvaltab effect increases with simultaneous use of valproic acid and alcohol.
Monoamine oxidase inhibitors (MAO) prolong the effect of phenobarbital.
Phenobarbital enhances the action of local anesthetic anesthetics and analgesics.
While taking phenobarbital with gold medications at the same time, the risk of kidney damage increases.
Rifampicin may lower the effect of phenobarbital.
The combined use of phenobarbital with zidovudine can increase the toxicity of both drugs.
With prolonged simultaneous use of phenobarbital with nonsteroidal anti-inflammatory drugs, there is a risk of bleeding and stomach ulcers.
Corvaltab increases the toxicity of methotrexate.
Terms and conditions of storage
Keep out of reach of children at temperature up to 25 ° C.
Shelf life - 2 years.